Ibrutinib selectively and irreversibly targets EGFR (L858R, Del19) mutant but is moderately resistant to EGFR (T790M) mutant NSCLC Cells

Through comprehensive comparison study, we found that ibrutinib, a clinically approved covalent BTK kinase inhibitor, was highly active against EGFR (L858R, del19) mutant driven NSCLC cells, but moderately active to the T790M ‘gatekeeper’ mutant cells and not active to wild-type EGFR NSCLC cells. Ib...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Oncotarget
Autores principales: Wu, Hong, Wang, Aoli, Zhang, Wei, Wang, Beilei, Chen, Cheng, Wang, Wenchao, Hu, Chen, Ye, Zi, Zhao, Zheng, Wang, Li, Li, Xixiang, Yu, Kailin, Liu, Juan, Wu, Jiaxin, Yan, Xiao-E, Zhao, Peng, Wang, Jinhua, Wang, Chu, Weisberg, Ellen L., Gray, Nathanael S., Yun, Cai-Hong, Liu, Jing, Chen, Liang, Liu, Qingsong
Formato: Artigo
Lenguaje:Inglês
Publicado: Impact Journals LLC 2015
Materias:
Research Paper
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC4741607/
https://ncbi.nlm.nih.gov/pubmed/26375053
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares